Related Experiment Video
Updated: Jul 13, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C treatment: shorter and better?
Evaldo Stanislau Affonso de Araújo1, Cláudia Courtouké, Antonio Alci Barone
1Outpatient Hepatitis Clinic, Department of Infectious and Parasitic Diseases, Hospital das Clínicas, School of Medicine, University of São Paulo, SP, Brazil. evaldostanislau@uol.com.br
Summary
This study shows that early virologic response (EVR) can optimize hepatitis C virus (HCV) treatment. Tailored, shorter treatment durations based on EVR improve patient outcomes and reduce costs.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C virus (HCV) infection requires effective treatment strategies.
- Optimizing treatment duration can improve patient outcomes and reduce healthcare costs.
Purpose of the Study:
- To evaluate an abbreviated therapeutic approach for chronic HCV infection.
- To discuss the utility of early virologic response (EVR) in managing HCV treatment.
- To review HCV viral kinetics and their role in treatment optimization.
Main Methods:
- Synthesis of two publications evaluating abbreviated HCV treatment.
- Analysis of early virologic response (EVR) at week 4.
- Review of HCV viral kinetics and treatment response.
Main Results:
- Week 4 EVR (undetectable HCV RNA) predicts sustained viral response.
- HCV genotype 1 with low viral load treated for 24 weeks.
- HCV genotypes 2 or 3 treated for 12 weeks.
- Abbreviated regimens optimize patient management and reduce treatment failures.
Conclusions:
- Early virologic response (EVR) enables optimized, abbreviated treatment for hepatitis C.
- Shorter treatment durations improve patient outcomes and reduce costs.
- This approach minimizes patient exposure to potentially toxic drugs.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...